Early initiation of second-line therapy in primary immune thrombocytopenia: insights from real-world evidence

To compare patients with primary immune thrombocytopenia (ITP) prescribed early (within 3 months of initial ITP treatment) second-line treatment (eltrombopag, romiplostim, rituximab, immunosuppressive agents, splenectomy) with or without concomitant first-line therapy to those who received only firs...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuker, Adam, Buckley, Brian, Mousseau, Marie-Catherine, Barve, Aditya Anand, Haenig, Jens, Bussel, James B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345059/
https://www.ncbi.nlm.nih.gov/pubmed/37300567
http://dx.doi.org/10.1007/s00277-023-05289-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10345059/
https://www.ncbi.nlm.nih.gov/pubmed/37300567
http://dx.doi.org/10.1007/s00277-023-05289-0

Ejemplares similares